Predictive value of MMP-2, MMP-9, TIMP-1 in surgical treatment of localized renal cell cancer

Purpose of the study. To determine the association of individual biomolecular markers of oncogenesis MMP‑2, MMP‑9 and the inhibitor of metalloproteinases TIMP‑1 with the risk of tumor invasion and metastasis in the early and late postoperative period in various types of surgical treatment of RCC.

Materials and methods. The study prospectively included medical data of 60 patients with kidney cancer with T1-3N0 M0 who received surgical treatment at the Urology Clinic of the S.R.Mirotvortsev Design Bureau of the SSMU from 2016 to 2019. The patients were divided into 3 groups: 1st group included 20 patients who underwent kidney resection for elective indications, with tumors of the renal parenchyma; 2nd group – 20 patients who underwent radical nephrectomy by laparoscopic approach; Group 3-20 patients who underwent radical nephrectomy with lumbotomy access. All patients being in the early (7-10th day) and long-term postoperative period (after 1 and 2 years) by solid-phase ELISA, on a StatFax 4200 analyzer using eBiosence and Cloud-Clone Corp reagent kits, a study was made on the basis of the concentration in the blood serum of markers of oncogenesis MMP‑2, MMP‑9 and TIMP‑1 metalloproteinase inhibitor.

Results. In all groups of patients with RCC, an initial increase in the concentration of MMP‑9 was revealed compared to the control (p≤0.05). According to the results of the ROC analysis, this indicator has a high specificity and sensitivity in terms of predicting RCC at the preoperative stage. The highest sensitivity and specificity for detecting tumor progression was demonstrated by matrix metalloproteinases: MMP‑2 – sensitivity 96 %, specificity 67 % (cut-off point 357.5 pg/ml) and MMP‑9 – sensitivity 87.5 % and specificity 62 % (cut-off point 958 ng/ml). At the same time, TIMP‑1 showed less significant indicators – sensitivity and specificity (74 % and 60 %, respectively) with a cut-off point of 0.49 ng/ml.

Conclusion. Serum MMP‑2 and MMP‑9 are a marker of a poor prognosis for the progression of RCC. Elevated levels of MMP‑9 in the blood serum of RCC patients before and after various types of surgical treatment reflect the individual characteristics of the patient’s body and the tumor process. Dynamic monitoring of the level of markers of oncogenesis in patients with RCC allows a personalized approach to the choice of the scope and method of surgical treatment of RCC.

1. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016 Feb 27;387(10021):894–906. https://doi.org/10.1016/S0140-6736(15)00046-X

2. Rubtsova NA, Kryaneva EV, Golbits AB, Alekseev BY, Kostin AA, Kaprin АD. The R.E.N.A.L. nephrometry score in radiologist’s practice. Cancer Urology. 2020;16(4):17–31. (In Russian). https://doi.org/10.17650/1726-9776-2020-16-4-17-31

3. Ran L, Liang J, Deng X, Wu J. miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma. Biomed Res Int. 2017;2017:4832931. https://doi.org/10.1155/2017/4832931

4. Xu C-L, Chen L, Li D, Chen F-T, Sha M-L, Shao Y. Acyl-CoA Thioesterase 8 and 11 as Novel Biomarkers for Clear Cell Renal Cell Carcinoma. Front Genet. 2020;11:594969. https://doi.org/10.3389/fgene.2020.594969

5. Teng J, Gao Y, Chen M, Wang K, Cui X, Liu Y, et al. Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma. Chin Med J. 2014;127(9):1640–1644.

6. Gershtein ES, Naberezhnov DS, Alferov AA, Bezhanova SD, Frolova NF, Matveev VB, et al. Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients. Cancer Urology. 2020;16(4):39–47. (In Russian). https://doi.org/10.17650/1726-9776-2020-16-4-39-47

7. Evsyukova ОI, Matveev VВ. Renal cell carcinoma: what’s new in 2019. Cancer Urology. 2019;15(4):120–125. (In Russian). https://doi.org/10.17650/1726-9776-2019-15-4-120-125

8. Lughezzani G, Jeldres C, Isbarn H, Perrotte P, Shariat SF, Sun M, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009 Oct;182(4):1287–1293. https://doi.org/10.1016/j.juro.2009.06.018

9. Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019 Sep;16(9):539–552. https://doi.org/10.1038/s41585-019-0211-5

10. Qiao Z, Li Y, Lu H, Wang K, Xu W. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J Surg Oncol. 2013 Jan 3;11:1. https://doi.org/10.1186/1477-7819-11-1

11. Jiang B, Liu J, Lee MH. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy. Molecules. 2019 Jan 11;24(2):255. https://doi.org/10.3390/molecules24020255

12. Glybochko PV, Zacharova NB, Ponukalin AN, Durnov DA, Shachpazyan NK. Diagnostic value of angiogenesis rates in renal-cell carcinoma. Cancer Urology. 2011;7(3):25–30. (In Russian). https://doi.org/10.17650/1726-9776-2011-7-3-25-30

13. Tarasenko AI, Napsheva AM, Berezinetz OL, Ponukalin AN, Medvedeva AV, Zakharova NB. Biomarkers of renal damage and immunohistochemical detection of oncogenesis in the surgical treatment of renal cell carcinoma. Saratov Scientific and Medical Journal. 2018;14(3):420–426. (In Russian).

14. Chen Y, Lu H, Tao D, Fan M, Zhuang Q, Xing Z, et al. Membrane type-2 matrix metalloproteinases improve the progression of renal cell cancer. Int J Clin Exp Pathol. 2017;10(10):10618–10626.

15. DI Carlo A. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett. 2013 May;5(5):1677–1681. https://doi.org/10.3892/ol.2013.1252

16. Cherdantseva TM, Bobrov IP, Varlamov SV, Myadelets MN, Klimachev IV, Avdalyan AM, et al. Prognostic value of matrix metalloproteinase 9 in renal cell carcinoma. Cancer Urology. 2018;14(3):17-24. (In Russian). https://doi.org/10.17650/1726-9776-2018-14-3-17-24

17. Wu D, Pan H, Zhou Y, Zhou J, Fan Y, Qu P. microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep. 2014 Jun;9(6):2491–2498. https://doi.org/10.3892/mmr.2014.2116

18. Kawata N, Nagane Y, Hirakata H, Ichinose T, Okada Y, Yamaguchi K, et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology. 2007 Jun;69(6):1049–1053. https://doi.org/10.1016/j.urology.2007.02.044

19. Kogan MI, Akhokhov ZM, Gusev AA, Pasechnik DG. Biomolecular prognostic factors in renal cell carcinoma: a literature review. Cancer Urology. 2016;12(3):45-51. (In Russian). https://doi.org/10.17650/1726-9776-2016-12-3-45-51

20. Liu X, Huang X, Zhao P, Zhang P. Survival benefit of nephron-sparing surgery for patients with pT1b renal cell carcinoma: A population-based study. Oncol Lett. 2020 Jan;19(1):498–504. https://doi.org/10.3892/ol.2019.11065

21. Banyra OB, Stroy AA, Shulyak AV. Markers of tumor growth in the diagnosis of kidney cancer. Experimental and Clinical Urology. 2011;4:72–88. (In Russian).

22. Lin H, Pan J, Zhang F, Huang B, Chen X, Zhuang J, et al. Matrix metalloproteinase-9 is required for vasculogenic mimicry by clear cell renal carcinoma cells. Urol Oncol. 2015 Apr;33(4):168. e9-168.e16. https://doi.org/10.1016/j.urolonc.2014.12.007

23. Miyake H, Nishikawa M, Tei H, Furukawa J, Harada K, Fujisawa M. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. Urol Oncol. 2014 Jul;32(5):584–588. https://doi.org/10.1016/j.urolonc.2014.01.016

24. Chan Y-C, Chen C-W, Chan M-H, Chang Y-C, Chang W-M, Chi L-H, et al. MMP2-sensing up-conversion nanoparticle for fluorescence biosensing in head and neck cancer cells. Biosens Bioelectron. 2016 Jun 15;80:131–139. https://doi.org/10.1016/j.bios.2016.01.049

25. Chen Q, Zhao X, Zhang H, Yuan H, Zhu M, Sun Q, et al. MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Mol Carcinog. 2015 Nov;54(11):1292–1300. https://doi.org/10.1002/mc.22204

26. Chen Y, Lu H, Tao D, Fan M, Zhuang Q, Xing Z, et al. Membrane type-2 matrix metalloproteinases improve the progression of renal cell cancer. Int J Clin Exp Pathol. 2017;10(10):10618–10626.

27. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016 Feb 1;97:4–27. https://doi.org/10.1016/j.addr.2015.11.001

28. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001 Oct;7(10):3113–3119.

29. Gershtein ES, Mushtenko VV, Korotkova EA, Bezhanova SD, Morozov AA, Alferov AA, et al. Matrix metalloproteinases 2, 7, 8, 9 and their type 1 tissue inhibitor in serum of renal cancer patients: clinical and pathologic correlations. Almanac of Clinical Medicine. 2017;45(2):94–101. (In Russian). https://doi.org/10.18786/2072-0505-2017-45-2-94-101

30. Ellis RJ. Chronic kidney disease after nephrectomy: a clinically-significant entity? Transl Androl Urol. 2019 May;8(Suppl 2):S166–S174. https://doi.org/10.21037/tau.2018.10.13